1. Background
Development process of a nutritional therapy
Evaluation of new nutritional therapies on tumor development and growth requires preclinical studies focusing on physical, chemical, pharmacodynamic, pharmacokinetic and toxicological analyses. Part of them can be conducted in vitro, but they have to be validated in an animal model before initiating clinical trials.
Needs for an alternative to animal experimentation
Dose-response determination of the treatment relevance, toxicity and schedule (i.e. doses, route and timing) requires a substantial number of animals undergoing experiments of severity degrees 2 to 3. In 2011, 1,105,921 animals were used in cancer research (17.8% of all animals used for studies of diseases) according to the report of the European Statistics Commission on the number of animals used for experimental and other scientific purposes in the Member States of the United Europe [1] . Therefore, new alternative methods to avoid animal suffering and sacrifice and implement the 3R principle (Reduce, Refine, Replace) are welcome. We present here a transition method between in vitro and in vivo experiments that allows to quickly assess the treatment feasibility and to provide an estimate therapeutic dose before further in vivo evaluation.
The CAM model
The chick embryo chorioallantoic membrane (CAM) model is used in the pharmaceutical research for the evaluation of drug delivery systems, because this in ovo method is close to the in vivo conditions, cheap (egg purchasing and maintenance), simple (extra-embryonic, highly vascularized) and rapid to implement [2] . Moreover, utilization of the CAM model does not require tedious administrative procedures for obtaining ethics committee approval for animal experimentation, because the chick embryo is not considered as living animals until Embryo Development Days (EDD) 17 in most countries. This particular feature allows for rapid adaptations of the experimental protocol according to the results obtained. In total, the chicken embryo takes 21 days from the beginning of incubation to the hatching. CAM appears between EDD 4 and 5. This transparent and highly vascularized membrane in direct contact with the eggshell is the respiratory system allowing embryo to gas exchange. This is the reason why CAM is widely used to study angiogenesis, but also wound healing [3] , tissue engineering [4] , biomaterials [5] , implants [6] and biosensors [7] .
The CAM model in cancer research
One of the advantages of the CAM model is the lack of mature immunity (it lacks both B and T cellmediated immune functions) up to EDD 18 when the chicken embryo becomes immunocompetent. However, the presence of T and B cells can already be detected at EDD 11 and 12. This feature allows the xenografting of human tumors on the CAM surface. Thus, the pharmaceutical effects of new drug formulation can be evaluated not only on CAM vasculature, but also on embryo development and xenografted tumors.
Advantages of the CAM compared to mammalian models
Mammalian models are broadly used for preclinical evaluation of drug formulation but those models are expensive, time-consuming and associated with administrative burden with respect to ethical and legal aspects. The CAM model allows to overcome these tedious steps until EDD 17 and to obtain tumors more rapidly and at low cost. Indeed, xenografted tumors take only three to five days to grow after cancer cell grafting and are visible to the naked eye, whereas tumors can take much more time to develop in mammalian models [8] . The CAM model is increasingly used to study the migrating and angiogenic potential of most of the human cancers including lung [9] , ovarian [10, 11] , cervical [12] , breast [13] , prostate [14] and colorectal tumors [15, 16] . The CAM model is particularly relevant for studying metastasis, because the majority of cancer cells (>80%) extravasate 1e3 days after their intravenous injection and migrate through the mesenchyme to attach to arterioles in distant organs [17] . Thus, the CAM model is a good alternative to test new nutritional therapies in cancer research. Moreover, the U.S. Food and Drug Administration (FDA) has approved products pre-clinically evaluated in the CAM model and released a FDA guidance for industry in 2006 for the treatment of chronic cutaneous ulcer and burn wounds [18] .
Limitations of the CAM model
The main limitation of the use of the CAM model in cancer research is the reproducibility of the tumor grafting from one egg to another. The grafting rate and tumor size are not always high and uniform within an experiment. Moreover, the CAM does not tolerate well changes in pH, osmolarity, keratinization and oxygen tension, which can occur when the shell is opened or sealed [19] . Actually, successful grafting depends in great part on the operator's skill and the type of cancer cell line used. Moreover, despite the immaturity of the chick immune system, non-specific inflammatory reaction can occur as a result of the tumor grafting and induce unspecific angiogenesis with infiltrating leukocytes [20] . Thus, tumor neovascularization can hardly be distinguishable from unspecific angiogenesis, especially as the tumor is grafted at the intersection of existing blood vessels whose vascular density and course within the CAM mesenchyme change during embryo development [21] . One way to avoid non-specific inflammatory response is to graft the tumor just at the onset of CAM development whilst the immune system of the embryo is still immature and to document vessel formation by sequential camerawork [21] . However, the time between the grafting and chick hatching (8e10 days) is short and the interactions between immune and cancer cells cannot be evaluated [10] . Moreover, the current methods of investigation in the CAM model are often based on score measurements of visual or microscopic observations. The results are relatively subjective and a high inter-individual variability in the vessel counting or tumor size measurement can be noticed from one operator to another. It is important to always perform experiments on the same EDD, because CAM development is characterized by rapid morphological changes [22] . In cancer research, the main drawbacks are therefore the variability in tumor grafting and the limitation of 2-D tumor growth measurement at the CAM surface, whereas the tumor often grows through the CAM mesenchyme.
Improving the CAM model for studying treatment effects on tumor growth
Some improvements can be made to make the CAM model more attractive for cancer research, so that it can be used more readily to evaluate the effect of different treatments on tumor development, growth and vascularization. We recently developed a 3-D imaging of the tumors xenografted on the CAM, using positron emission and computed tomography (microPET/CT). The reproducibility of tumor grafting was improved by implanting tumor spheroids in the CAM. Such an innovative approach would provide an alternative to the time-consuming and expensive evaluation of new anticancer treatments in animals before initiating clinical trials (Fig. 1 ).
Methodological approach

Tumor spheroid production
Currently, the most commonly used method in cancer research is the 2-D monolayer cell culture, where cells nonspecifically adhere to rigid plastic well plates and lose the gene expression profile and morphology present in real tumors. To better mimic physiological conditions, methods of multicellular spheroid production have been developed, using 3-D culture where cells are suspended in extracellular matrix, which provides ligands and malleable surface. It has been demonstrated that the addition of extracellular matrix proteins promotes cellecell bonds, cell aggregation and spheroid formation for cancer cell lines that were previously considered incompatible with such culture condition [23] . To are cultured in standard cell culture medium supplemented with 10% heat-inactivated fetal bovine serum and 0.1 g/L penicillin-streptomycin. Cells are kept at 37 C in a humidified air containing 5% CO 2 and maintained in exponential growth phase. For the production of one tumor spheroid/well, cells are harvested, resuspended at a density of 3000 cells/50 mL/well in the extracellular matrix, and then cultured for 48e72 h in a 96-well spheroid formation plate. The initial number of cells per wells and the incubation time can be adjusted to monitor the tumor spheroid diameter. We recommend producing tumor spheroids of at least 500 mm diameter to obtain well-to-well size uniformity and diffusion gradients for pH, oxygen, nutrients and catabolites that will establish heterogeneous cell population with proliferating cells at the spheroid surface, quiescent cells in the deeper layers and hypoxic cells in the core [24] . This straightforward method can reproducibly allow generating tumor spheroids in high quantities.
CAM preparation
CAM method implementation previously requires the purchase of a specially egg-dedicated incubator and the possibility to order fertilized hen eggs from a pet supplier. Fertilized eggs are placed with the narrow apex down and rotated 180 automatically every 6 h in the incubator at 37 C and 65% relative humidity. From the first EDD, eggs are candled and the embryo motility is checked for viability every 24 h. The heartbeat and beak length can be measured with a digital egg monitor or with microCT imaging to check for normal embryo development. At EDD 4, a 3-mm hole is drilled in the eggshell at the narrow apex, cleaned with alcohol and protected with adhesive tape to avoid desiccation and contamination. Eggs are incubated again but this time in stationary mode and narrow apex upwards. At EDD 8, the hole is enlarged to 1e2 cm and CAM is scratched close to a blood vessel or around a junction of several blood vessels. The tumor spheroid is deposited in this space, surrounded or not by a silicone O-ring. After tumor spheroid deposit, the window on the eggshell is sealed with parafilm and eggs are returned to the incubator until EDD 11e12.
In ovo treatment
Depending on the tumor development, the treatment schedule can start around EDD 11e12. The nutrient mixture can be inoculated (20e50 ml) directly into the cavity of the allantoic vesicle to reach the tumor and the whole vascular area uniformly [25] . It can also be administered topically by placing a cotton wool soaked with the nutrient mixture to the CAM surface or intravenously, optionally in combination with a chemotherapeutic drug. Intravenous administration is performed in the main blood vessel of the CAM, through catheter or through a 33 00 gauge needle at a volume of 20e50 ml. The drug dose is adjusted according to the related antitumor and toxic effects on the chicken embryo. The embryo survival rate is evaluated 24 h after the intravenous administration of the drug. Eggs can be also treated by fractionated-dose radiotherapy according to current clinical practice, using X-ray irradiator [15] . For example, we are using fractionated-doses of 2e6 Gy/day, using a SRT100 Topex irradiator (Inc-30, 70, 100 kV X-rays). However, radiation protection of the chick embryo is problematic and dose calculation must take into account the eggshell attenuation. Dose homogeneity can be obtained by alternative irradiation from opposite egg sides. The dose and fraction are adjusted according to the related antitumor and toxic effects. A control dosimetry has to be performed by implanting micro dosimeters in the CAM. During the whole course of the experiment, the tumor surface is measured repeatedly according to the following equation (Fig. 2) :
Eggs are checked daily and weighed at the treatment onset and end. Blood samples of~0.5 ml can be collected from the CAM vein and stored at À80 C for further analyses. At the end of treatment, tumors and healthy embryo organs can be weighed, mechanically and enzymatically disaggregated into a single cell suspension or fixed with 4% paraformaldehyde and embedded with paraffin for further analyses, such as histology, immunohistochemistry or gene expression analysis using chicken Affymetrix microarrays. Drug content may also be analyzed after tissue lysis to have access to pharmacokinetic and biodistribution data.
Evaluation of tumor angiogenesis
Tumor vascularization is usually evaluated using fluorescence microscopy (angiography) after intravenous injection of sulforhodamine. Tumor vasculature pictures are recorded at different times (1, 5, 10 min) after injection, using a CCD camera coupled with a fluorescence microscope. The excitation wavelength is set between 525 and 560 nm, using a dichroic mirror (570 nm) and an emitter HQ 610/ 75 m filter (570e650 nm). To visualize the signal amplitude, two filters are added successively, the first one ND4 and the second ND8. Before injection, tissue autofluorescence is recorded. Data acquisition and measurement are done at 24, 48 and 72 h after treatment using a binocular microscope. Eggs can be kept up to half an hour out of the incubator for observation. When they are placed back into the incubator, the hole has to be covered with parafilm. Fig. 2 . Changes in tumor size in the CAM at 24 h, 48 h and 72 h after a new treatment (red) compared with shame treatment (blue). Fluorescence microscopy after sulforhodamine injection indicates that the tumor surface growth tends to stop and even decrease three days after treatment, compared to control.
Immunohistochemical analyses
Protein expression involved in different mechanisms, such as cell proliferation, inflammation or angiogenesis, can be assessed by immunohistochemical analyses of tumor and host tissue samples.
After treatment allowing specific antigene binding, tissue sections of 5 mM are incubated overnight in a humidified chamber at 4 C with primary antibodies. It has to be noted that the availability of antibodies to chicken tissues may preclude some analyses in the CAM model [26] . However, We use the Universal LSAB-HRP system (Dako) to detect the signals according to manufacturer's instructions. To determine protein expression in tissue sections, coloration is captured with a Mirax Scanner (Zeiss), and positively stained cells of 10 different fields per tissue section are quantified using the Metamorph ® imaging software.
MicroPET/CT imaging in the CAM model
To date, only 2-D measurement of the tumor growth has been carried out in the CAM model. As surface measurement do not take into account tumor invasion of the chorionic epithelium and mesenchymal connective tissue below the CAM [27] , we recently performed a 3-D evaluation of the tumor growth using positron emission and computed tomography (microPET/CT) with the commonly-used PET tracer [
18 F]-fluorodeoxyglucose ([ 18 F]FDG) and the contrast agent Telebrix-38 (Fig. 3) . Alternatively, tumor vascularization can also be evaluated with VEGF or Integrin kits for PET imaging. Eggs were fixed on an animal bed for microPET/CT and injected intravenously with 3
Fig . 3 . MicroPET/CT imaging in the CAM model after an intravenous injection of 3 MBq [
18 F]FDG and 50 ml of Telebrix-38. After MicroPET/CT acquisition, the tumor volume and uptake were measured as 87 ml and 7781 KBq/ml.
MBq of [
18 F]FDG and 50 ml of the contrast agent Telebrix-38 (meglumine ioxitalamate; Tyco healthcare, QC, Canada). Immediately after injection, a 1-h PET scan was performed using the Triumph ® LabPET8/CT/SPECT system (GE Healthcare, Waukesha, USA). After data acquisition, PET data were reconstructed with the maximum a posteriori (MAP) reconstruction algorithm. The pixel size was 0.866 Â 0.866 Â 0.796 mm and in the center field of view the resolution was 1.4 mm full-widthat-half-maximum. Following the microPET scan, a 10-min CT scan was performed with the following parameter settings: 360 rotation steps, tube voltage 80 kV, tube current 500 mA, binning 4, and exposure time 310 ms. The pixel size was 0.091 Â 0.091 Â 0.091 mm. MicroPET/CT images were fused using the OsiriX imaging analysis software developed at the CIBM platform of the Geneva University Medical Center. Before fusion region of interests (ROIs) were drawn on the PET pictures manually by qualitative assessment covering the whole tumor and subsequently tumor volume and tracer uptake, assessed by standard uptake values (SUV) mean and maximum, were generated by summation of voxels within the tomographic planes. Another study was recently published, which confirms the feasibility of microPET/CT imaging in human gliobastoma xenografted CAM, using different PET tracers [28] .
Overall value of the CAM
Novel anticancer treatments are mostly evaluated in tumor-bearing mice using a tumor growth delay assay or different imaging technologies prior to passage in clinical trials. However, establishment of experimental parameters, such as the treatment schedule (i.e. type, route, dose and timing), is an expensive, time-consuming and tedious process that requires, as a prerequisite, ethics committee approval for animal experimentation. To date, the CAM model was not an optimal alternative due to several drawbacks, especially poor tumor size homogeneity and only 2-D tumor measurement on the CAM surface. Improving the CAM model by using tumor spheroid grafting and microPET/CT would provide a simple, reliable, reproducible and quantitative method for obtaining doseeresponse analysis and estimating the treatment schedule (i.e. type, route, dose and timing) before initiating clinical trials. This method is particularly suitable for evaluating rapidly the effect of nutritional therapies on tumor development, growth, vascularization and metastasis. Although experimentation in the CAM model is probably not sufficient for in-depth evaluation of long-term treatment related side effects and toxicity on healthy organs and tissues, it may contribute to implement the 3R principle (Reduce, Refine, Replace) by reducing the number of animal suffering and sacrifice.
Conclusion
The use of tumor spheroid grafting and microPET/CT imaging in the CAM model may provide a rapid and low-cost alternative to avoid animal suffering and sacrifice for testing nutritional therapy in cancer research.
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